Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CLGN 
Collplant Biotechnologies Ltd (CLGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: CLGN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -67.75% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 29.44M USD | Price to earnings Ratio - | 1Y Target Price 14 |
Price to earnings Ratio - | 1Y Target Price 14 | ||
Volume (30-day avg) 9822 | Beta 0.7 | 52 Weeks Range 2.54 - 6.75 | Updated Date 04/1/2025 |
52 Weeks Range 2.54 - 6.75 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.45 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-03-26 | When - | Estimate -0.13 | Actual -0.34 |
Profitability
Profit Margin - | Operating Margin (TTM) -2423.17% |
Management Effectiveness
Return on Assets (TTM) -40.81% | Return on Equity (TTM) -79.46% |
Valuation
Trailing PE - | Forward PE 15.55 | Enterprise Value 20610095 | Price to Sales(TTM) 57.16 |
Enterprise Value 20610095 | Price to Sales(TTM) 57.16 | ||
Enterprise Value to Revenue 40.02 | Enterprise Value to EBITDA -5.97 | Shares Outstanding 11454500 | Shares Floating 7651729 |
Shares Outstanding 11454500 | Shares Floating 7651729 | ||
Percent Insiders 10.16 | Percent Institutions 12.23 |
Analyst Ratings
Rating 4.5 | Target Price 12.5 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Collplant Biotechnologies Ltd
Company Overview
History and Background
Collplant Biotechnologies Ltd. was founded in 2004 in Israel. It focuses on recombinant human collagen (rhCollagen) based products and technologies for regenerative and aesthetic medicine. Significant milestones include developing and patenting its plant-based rhCollagen technology and advancing products through clinical trials.
Core Business Areas
- Regenerative Medicine: Development of rhCollagen-based products for tissue repair and regeneration, including orthopedic and wound healing applications.
- Aesthetic Medicine: Development of rhCollagen-based products for aesthetic procedures such as dermal fillers.
- Bioprinting: Using rhCollagen as a bioink for 3D bioprinting of tissues and organs.
Leadership and Structure
Yehiel Tal is the Chief Executive Officer. The company has a board of directors and various departments including research and development, clinical operations, and commercialization.
Top Products and Market Share
Key Offerings
- Vertebral Body: rhCollagen-based product currently partnered with Stryker (SYK) for spinal fusion procedures. Stryker holds the exclusive license. Competitors include Medtronic (MDT), Johnson & Johnson (JNJ).
- CollaFill: Dermal filler under development. Competitors include Allergan (ABBV) and Galderma.
- BioInk: rhCollagen bioink for 3D bioprinting. This market is still emerging. Competitors include BICO (formerly CELLINK) and 3D Systems (DDD).
Market Dynamics
Industry Overview
The regenerative medicine market is experiencing significant growth, driven by aging populations and increasing demand for advanced therapies. The aesthetic medicine market is also growing, fueled by consumer desire for minimally invasive cosmetic procedures.
Positioning
Collplant is positioned as a developer of novel rhCollagen-based products. Their competitive advantage lies in the purity and human identity of their rhCollagen, potentially reducing immune response and improving efficacy.
Total Addressable Market (TAM)
The total addressable market for regenerative medicine and aesthetic medicine is estimated to be in the billions of dollars. Collplant is targeting specific segments within these markets, aiming to capture a portion of the market through its proprietary rhCollagen technology.
Upturn SWOT Analysis
Strengths
- Proprietary rhCollagen technology
- Partnership with Stryker
- Potential for improved safety and efficacy compared to animal-derived collagen
Weaknesses
- Limited financial resources
- Reliance on partnerships for commercialization
- Clinical trial and regulatory risks
Opportunities
- Expanding into new therapeutic areas
- Developing new rhCollagen-based products
- Partnering with additional companies
Threats
- Competition from established players
- Regulatory hurdles
- Clinical trial failures
Competitors and Market Share
Key Competitors
- ABBV
- JNJ
- MDT
- SYK
- BICO
- DDD
Competitive Landscape
Collplant faces significant competition from larger, more established companies. Its advantage lies in its proprietary rhCollagen technology, which may offer improved safety and efficacy. However, Collplant needs to secure more strategic partnerships and approvals to achieve significant market share.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been dependent on partnership deals and clinical trial progress.
Future Projections: Future growth is dependent on successful clinical trials, regulatory approvals, and commercialization efforts. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing clinical trials for rhCollagen-based products and expanding partnerships.
Summary
Collplant Biotechnologies is a regenerative medicine company with a focus on recombinant human collagen. Its technology is promising but reliant on clinical trial success and partnerships for commercialization. It is in an emerging market with both big competitors such as Johnson and Johnson and smaller niche market contenders, such as BICO. With the Stryker relationship going well, its future looks promising but needs to be monitored closely for future developments.
Similar Companies
ABBV
AbbVie Inc
ABBV
AbbVie Inc
DDD
3D Systems Corporation
DDD
3D Systems Corporation
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
MDT
Medtronic PLC
MDT
Medtronic PLC
SYK
Stryker Corporation
SYK
Stryker Corporation
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- Public News Articles
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual risk tolerance and after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Collplant Biotechnologies Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2018-01-30 | CEO & Director Mr. Yehiel Tal | ||
Sector Healthcare | Industry Biotechnology | Full time employees 57 | Website https://www.collplant.com |
Full time employees 57 | Website https://www.collplant.com | ||
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was incorporated in 1981 and is headquartered in Rehovot, Israel.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.